2501-P: CARF (CDKN2AIP) Reprograms Hepatic Oxidative Metabolism to Limit Steatosis in Obese Mice
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2501-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JERRY SALINAS und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in obesity, and impaired mitochondrial fatty acid β-oxidation (FAO) is a key contributor to its pathogenesis. Building on our prior report that CARF loss exacerbates steatosis and CARF overexpression improves metabolic phenotypes, we tested whether CARF mitigates obesity-associated hepatic steatosis by reprogramming mitochondrial FAO pathways.
Methods
CARF was knocked down in hepatocytes, and changes in FAO pathway gene expression were assessed by transcriptomics. Palmitate-driven FAO was measured by Seahorse oxygen consumption rate (OCR) after CARF overexpression. Diet-induced obese (DIO) mice were fed a high-fat diet (HFD) for 16 weeks (n=8/group) and received liver-directed CARF overexpression (AAV-CARF; HFD-COE) or vector control. Hepatic triglyceride (TG), liver histology (H & E staining), RNA sequencing, RT-CCR, and western blotting for CARF/FAO pathway genes, and metabolomics profiling were assessed.
Results
CARF ablation significantly suppressed the FAO/PPAR pathway genes, including CPT2 and ACADM. RT-PCR and immunoblotting validated that CARF regulates CPT2 at the mRNA and protein levels. In agreement, CARF overexpression increased palmitate-driven OCR, indicating enhanced FAO. In DIO mice, CARF overexpression reduced hepatic TG burden and restored CPT2 protein levels compared with the vector controls. In addition, CARF-CPT2 restoration was accompanied by metabolite remodeling, with clear separation of NCD, HFD, and HFD-COE groups by PCA and heatmap. To provide mechanistic support, we observed that pharmacologic AMPK activation (AICAR) increased CARF/CPT2 levels and reduced TG, whereas AMPK inhibition (Compound C) decreased CARF/CPT2 levels and increased TG.
Conclusion
CARF activates a mitochondrial fatty acid oxidation program in obesity, restoring FAO flux and hepatic metabolite profiles while reducing steatosis—supporting CARF as a mechanistic, potentially druggable node in MASLD. Disclosure J. Salinas: None. D.M. Clayborn: None. T.C. Friedman: Advisory Panel; Ended; Acella Pharmaceuticals. K.M. Hasan: None. Funding NIGMS-5R16GM153632NIGMS-5SC2GM125551
Zitieren
APA
SALINAS, J., CLAYBORN, D. M., FRIEDMAN, T. C., & HASAN, K. M. (2026). 2501-P: CARF (CDKN2AIP) Reprograms Hepatic Oxidative Metabolism to Limit Steatosis in Obese Mice. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2501-p
Vancouver
SALINAS J, CLAYBORN DM, FRIEDMAN TC, HASAN KM. 2501-P: CARF (CDKN2AIP) Reprograms Hepatic Oxidative Metabolism to Limit Steatosis in Obese Mice. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2501-p
BibTeX
@article{SALINAS2026,
author = {SALINAS, JERRY and CLAYBORN, DANIELLE M. and FRIEDMAN, THEODORE C. and HASAN, KAMRUL M.},
title = {2501-P: CARF (CDKN2AIP) Reprograms Hepatic Oxidative Metabolism to Limit Steatosis in Obese Mice},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2501-p}
}
EUVIMED